<DOC>
	<DOCNO>NCT01198613</DOCNO>
	<brief_summary>It believe ragweed primary cause autumn allergies 87 % patient ragweed allergy suffer rhinoconjunctivitis . ToleroMune Ragweed novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment ragweed allergy . This study look efficacy , safety tolerability two dos ToleroMune Ragweed ragweed allergic subject follow challenge ragweed EEC .</brief_summary>
	<brief_title>ToleroMune Ragweed Exposure Chamber Study</brief_title>
	<detailed_description>This study design randomise , double-blind , placebo-controlled , parallel group study evaluate safety tolerability ToleroMune Ragweed ragweed allergic subject allergic rhinoconjunctivitis , subject may also control asthma . The efficacy ToleroMune Ragweed explore subject use ( Environmental Exposure Chamber ) EEC . The study consist 3 study period . In Period 1 , Screening perform maximum 12 week randomisation may consist one two visit clinic , Investigator 's discretion . Baseline Challenge consist 4 visit EEC least 3 day randomisation . In Period 2 , subject cohort comply inclusion/exclusion criterion randomise one five group receive treatment every 2 week ( Â±2 day ) 14 week . In Period 3 , Post Treatment Challenge consist 4 visit EEC 18-22 week first administration treatment period assessment perform identical baseline challenge . Follow-up conduct 3-10 day PTC .</detailed_description>
	<criteria>Inclusion criterion Male female , age 1865 year . Minimum 2year document history rhinoconjunctivitis exposure ragweed . [ Subjects may also control asthma Positive skin prick test ragweed allergen . Minimum qualify rhinoconjunctivitis symptom score Exclusion criterion History asthma . A history anaphylaxis ragweed allergen . Subjects FEV1 &lt; 70 % predict . Subjects tolerate baseline challenge EEC . Subjects administration epinephrine contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . A history severe drug allergy , severe angioedema anaphylactic reaction food . A history significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Ragweed allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Exposure chamber</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>ToleroMune Ragweed</keyword>
</DOC>